NKGen to Progress Alzheimer’s Candidate into Phase 2; Shares Surge 75%

Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate SNK01 has received Safety Review Committee clearance to progress into Phase 2 clinical development. The company is evaluating SNK01, a novel cell-based, patient-specific expanded autologous natural killer cell, immunotherapeutic drug candidate as a treatment for moderate Alzheimer’s disease. NKGen expects to enroll the first patient in the study in Q2 2024.

“We are excited to announce another important clinical milestone in our mission to advance SNK01 as the first potential disease modifying treatment of its kind for patients with more advanced Alzheimer’s disease,” said Paul Y. Song, MD, Chairman and CEO of NKGen.

“The Phase 2 trial will utilize our cryopreserved SNK01 product given at the highest dose we have ever delivered, and for a full year duration. To date, SNK01 has been found to be well-tolerated with no reported drug-related adverse events. We are also very encouraged with the clinical progress we have made to date in moderate Alzheimer’s disease research and look forward to generating additional significant clinical and biomarker data from our randomized placebo-controlled Phase 2 trial.”

The company’s Phase 2 trial will assess efficacy and further safety of SNK01 in a larger group of 30 patients with moderate Alzheimer’s disease using a randomized, double-blind design. NKGen stated that the Phase 2 trial will provide deep insights into the potential benefits and risks of SNK01 in moderate Alzheimer’s disease, helping clinical researchers to provide validation of the potential therapeutic value of SNK01.

About NKGen Biotech

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Share This Article


About the Author

NKGen to Progress Alzheimer’s Candidate into Phase 2; Shares Surge 75%

Catie Corcoran

Biotech Editor